Institut du Cerveau et de la Moelle épiniѐre (Institut du Cerveau – ICM) and Pfizer have announced a three-year scientific collaboration to investigate the fundamental mechanisms of certain neurodegenerative diseases, including Alzheimer’s, Parkinson’s and Huntington’s diseases, which are diseases with significant unmet medical need.
This collaboration brings together the Institut du Cerveau – ICM’s recognized translational medicine expertise, and Pfizer’s commitment and experience in neuroscience research in the development of medicines for neurological diseases.
All of the projects to be undertaken share the objective of better understanding the underlying processes which cause each disease in order to help enable the more efficient development of treatments. In some of the projects, the effects of medicines currently under development will be assessed.
A key study of the collaboration will aim to determine ways to identify Alzheimer’s disease patients at an early stage when future treatments which are targeted at preventing or slowing the disease might have a greater impact.
M. Alexis Brice, Directeur de l’Institut thématique Neurosciences d’AVIESAN
M. Brandricourt, Président et General Manager, Primary Care Business Unit, Pfizer
M. Bertrand Fontaine, Porteur de Projet IHU et Directeur Scientifique, Institut du Cerveau – ICM
In addition, researchers at Pfizer and Institut du Cerveau – ICM will collaborate to better understand the cellular mechanisms of other neurodegenerative diseases.
M. Bruno Dubois, coordinateur du projet de recherche Alzheimer
M. Brandricourt, Président et General Manager, Primary Care Business Unit, Pfizer
Pfizer‘s website